Pharma BD Deal Intelligence
A platform validator that petered out: BMS paid CytomX $50M upfront for Probody therapeutics against CTLA-4 and three other oncology targets, expanded the collaboration through 2021, but in May 2026 decided not to advance the remaining preclinical programs, ending it after $297.0M in aggregate payments.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →"Bristol is clearly not interested in putting all of its eggs in one basket" — the analysis frames the $1.2 billion CytomX deal as prudent diversification…
Deals mask CytomX's fundamental problem: in-house pipeline delivered little of value over 16 years, and 'until it does its shares will languish' — the masked…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
BMS paid CytomX $50M upfront plus research funding and up to $298M per target in development, regulatory and commercial milestones across four oncology targets including CTLA-4. The deal validated CytomX's Probody masked-antibody platform and was later expanded to eight targets in 2017 (and again in 2021).
CTLA-4 is a clinically validated immune-checkpoint receptor whose inhibition unleashes T-cell anti-tumor activity, but conventional anti-CTLA-4 therapy (ipilimumab/Yervoy) is limited by severe immune-related toxicities. Probody therapeutics aim to mask the antibody until protease activation in the tumor microenvironment, theoretically widening the therapeutic index across multiple solid tumors.
The CTLA-4 class is dominated by BMS's own Yervoy (ipilimumab), approved across melanoma, RCC, MSI-H CRC and HCC, typically combined with the PD-1 inhibitor Opdivo. AstraZeneca's tremelimumab (Imjudo) and several next-generation candidates (Agenus's botensilimab, Xencor's vudalimab) are pursuing better-tolerated CTLA-4 blockade. The 2014 BMS-CytomX deal granted BMS rights to a Probody version of CTLA-4 plus three additional oncology targets, with $50M upfront and up to $298M per-target in milestones (oncologypipeline.com / ApexOnco, 2024). The ambition was to differentiate via tumor-conditional activation, generating compounds such as BMS-986249 and the non-fucosylated BMS-986288. The 2017 expansion added eight new targets and a $200M upfront (genengnews.com, 2017-03-20), and a 2021 expansion further extended the platform. Despite the deal-size escalation, both lead CTLA-4 Probody candidates were ultimately discontinued in BMS portfolio reviews, and ApexOnco concluded that Probody platform deals had 'masked CytomX's fundamental problem' — namely that the masked-antibody approach has yet to demonstrate a clear safety advantage over standard antibodies (oncologypipeline.com, 2024-03-12). The deal nonetheless validated tumor-microenvironment-conditional biologics as a platform category and seeded years of follow-on financing for CytomX.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bristol-Myers Squibb Company / CytomX Therapeutics, Inc. (this deal) | 2014 | $1.2B | — |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Bristol-Myers Squibb Company / MyoKardia Inc. | 2020 | $13.1B | 76 |
| Bristol-Myers Squibb Company / Karuna Therapeutics | 2023 | $14.0B | 76 |
| Bristol-Myers Squibb Company / Ono Pharmaceutical Co., Ltd. | 2011 | — | 76 |
| Bristol-Myers Squibb Company / SystImmune Inc. | 2023 | $8.4B | 71 |
← Browse all deals · How we score deals
More: 2014 deals · Bristol-Myers Squibb Company deals · Oncology deals